{
  "docId": "019de075-814d-76ed-b6e6-6e437a6b6631",
  "docSlug": "56480dbdf83cce5ae4f2fad948f0ee58",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 26 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 26,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "appendix_methodology",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "Includes clinical trial data table and regulatory roadmap steps.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-814d-76ed-b6e6-6e437a6b6631/16",
  "deckHref": "/decks/019de075-814d-76ed-b6e6-6e437a6b6631",
  "deckJsonHref": "/decks/019de075-814d-76ed-b6e6-6e437a6b6631.json",
  "deckAnchorHref": "/decks/019de075-814d-76ed-b6e6-6e437a6b6631#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.43,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "list",
      "text": "Ovaprene prevented the requisite number of sperm from reaching the cervix across all women and all cycles evaluated. Specifically, in 100% of women and cycles, an average of less than five (< 5) progressively motile sperm (PMS) per high-powered field (HPF) were present in the midcycle cervical mucus collected two to three hours after intercourse with Ovaprene in place.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d10b59e-0909-40e2-a591-48bcc785f2e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.49,
        "y": 0.3
      },
      "kind": "list",
      "text": "Step 1 (Completed): PCT Study. Step 2 (Ongoing): 1. FDA approval of IDE, 2. Review study design, 3. Conduct pivotal study.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ece5b061-e99c-4539-ba28-9a56b44623d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.4,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "The PCT Clinical Study Met its Primary Endpoint",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "799c24a5-a643-4e4c-8bae-b4fb102b6cf0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.49,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Premarket approval (PMA) strategy. The Center for Devices and Radiological Health (CDRH) as lead review division.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a335cf1d-7410-4e4d-9f3d-c6142ceee65c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.95,
        "x": 0.05,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "1. Anticipated regulatory pathway and timelines. 2. Mauck C., Vincent K. Biology of Reproduction, Volume 103, Issue 2, August 2020, Pages 437-444",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fd0f8e3-c8c1-40ea-b091-8b15fbad490f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.44,
        "x": 0.06,
        "y": 0.65
      },
      "kind": "table",
      "text": "Baseline PCT's: 27.21, 23.20, 17.88, 24.80. Ovaprene PCT's: 0.48, 0.00, 1.18, 0.10.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e573757-b921-4dd5-bb39-a0214934e75e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.54,
        "x": 0.23,
        "y": 0.03
      },
      "kind": "title",
      "text": "Ovaprene - U.S. Regulatory Strategy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dac3352b-703d-4d6a-b010-e1058c164ff8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "480e03ed-613f-42a3-a16a-e09087f2af96",
      "evidence": "table/data: Baseline PCT's: 27.21, 23.20, 17.88, 24.80. Ovaprene PCT's: 0.48, 0.00, 1.18, 0.10.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}